Carbon Biosciences
As President & CEO, Mr. Yoon leads Solasta Ventures (formerly known as Aju IB Investment), one of the leading venture capital firms in South Korea. Based in Boston, Massachusetts, Mr. Yoon oversees Solasta’s investments with a focus on U.S. based life science companies and early-stage start-ups with novel science. Mr. Yoon also leads multiple cross-border strategic partnerships by leveraging his relationship with top-tier pharmaceutical companies in Korea. Currently, he is involved in multiple overseas venture capital fundraising projects by interacting with Korean governmental institutional funds as well as various private investors in Asia.
Additionally, Mr. Yoon is a board member of Arcellx, EvolveImmune Therapeutics, and Trefoil Therapeutics, and a board observer at several private biotechnology companies. Prior to Solasta Ventures, he spent more than twenty years in alternative (VC/PE) investments and healthcare corporate banking where he took numerous responsibilities in portfolio management, deal structuring, and fundraising. His previous experience includes venture investment management at Kibo Capital, the first venture fund in Korea; portfolio management with RBS Healthcare Banking Group; and venture accelerator program at Berwind Private Equity, a multi-generational family office located in Harvard, Massachusetts. Mr. Yoon earned his M.B.A. from Babson College, M.S.F. from Boston College, and B.S. in Chemical Engineering from Yonsei University in Seoul, Korea.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Carbon Biosciences
1 followers
Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.